Obesity induced T cell dysfunction and implications for cancer immunotherapy

Immunotherapy

Targeting T Cell Metabolism for Improvement of Cancer Immunotherapy

Front Oncol.

Le Bourgeois T, Strauss L, Aksoylar HI, Daneshmandi S, Seth P, Patsoukis N, Boussiotis VA

doi: 10.3389/fonc.2018.00237.

ImmunotherapyT Cells

Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells

J Autoimmun.

Alissafi T, Hatzioannou A, Legaki AI, Varveri A, Verginis P

doi: 10.1016/j.jaut.2019.102310.

Immunotherapy

Reprogramming T-cells for adoptive immunotherapy of ovarian cancer

Expert Opin Biol Ther.

Genta S, Ghisoni E, Giannone G, Mittica G, Valabrega G

Immunotherapy

Itacitinib (INCB039110), a JAK1 inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-Cell Therapy

Clin Cancer Res

Huarte E, O'Conner RS, Peel MT, Nunez-Cruz S, Leferovich J, Juvekar A, Yang YO, Truong L, Huang T, Naim A, Milone MC, Smith PA

doi: 10.1158/1078-0432.CCR-20-1739

T Cells

Functional genomic landscape of cancer-intrinsic evasion of killing by T cells

Nature.

Lawson KA, Sousa CM, Zhang X, Kim E, Akthar R, Caumanns JJ, Yao Y, Mikolajewicz N, Ross C, Brown KR, Zid AA, Fan ZP, Hui S, Krall JA, Simons DM, Slater CJ, De Jesus V, Tang L, Singh R, Goldford JE, Martin S, Huang Q, Francis EA, Habsid A, Climie R, Tieu D, Wei J, Li R, Tong AHY, Aregger M, Chan KS, Han H, Wang X, Mero P, Brumell JH, Finelli A, Ailles L, Bader G, Smolen GA, Kingsbury GA, Hart T, Kung C, Moffat J

doi: 10.1038/s41586-020-2746-2.

Immune Response

Trauma Induces Interleukin-17A Expression on Th17 Cells and CD4+ Regulatory T Cells as Well as Platelet Dysfunction

Front Immunol.

Hefele F, Ditsch A, Krysiak N, Caldwell CC, Biberthaler P, van Griensven M, Huber-Wagner S, Hanschen M

doi: 10.3389/fimmu.2019.02389.

Further Publications Rheumatology

Novel aspects of regulatory T cell dysfunction as a therapeutic target in giant cell arteritis

Ann Rheum Dis

Adriawan IR, Atschekzei F, Dittrich-Breiholz O, Garantziotis P, Hirsch S, Risser LM, Kosanke M, Schmidt RE, Witte T, Sogkas G

doi: 10.1136/annrheumdis-2021-220955

Immunotherapy

Replicating viral vector platform exploits alarmin signals for potent CD8+ T cell-mediated tumour immunotherapy

Nat Commun.

Kallert SM, Darbre S, Bonilla WV, Kreutzfeldt M, Page N, Müller P, Kreuzaler M, Lu M, Favre S, Kreppel F, Löhning M, Luther SA, Zippelius A, Merkler D, Pinschewer DD

doi: 10.1038/ncomms15327.

T Cells

Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis

Semin Cancer Biol.

Kumar P, Saini S, Prabhakar BS

doi: 10.1016/j.semcancer.

Related content

Targeting T Cell Metabolism for Improvement of Cancer Immunotherapy

Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells

Reprogramming T-cells for adoptive immunotherapy of ovarian cancer

Itacitinib (INCB039110), a JAK1 inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-Cell Therapy

Functional genomic landscape of cancer-intrinsic evasion of killing by T cells

Trauma Induces Interleukin-17A Expression on Th17 Cells and CD4+ Regulatory T Cells as Well as Platelet Dysfunction

Novel aspects of regulatory T cell dysfunction as a therapeutic target in giant cell arteritis

Replicating viral vector platform exploits alarmin signals for potent CD8+ T cell-mediated tumour immunotherapy

Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis